Compare Amgen, Inc. (AMGN) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Zeta Global Holdings Corp — how do they compare? Amgen, Inc. trades at $363.26 (market cap $196.12B), while Zeta Global Holdings Corp trades at $21.56 (market cap $5.36B). The key difference: Amgen, Inc. is far larger — about 36.6× Zeta Global Holdings Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| AMGN | ZETA | |
|---|---|---|
Market Cap | $196.12B | $5.36B |
Sector | Health | Technology |
52-Week High | $388.16 | $25.24 |
52-Week Low | $271.18 | $14.00 |
Enterprise Value | $241.41B | $5.27B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ZETA trades at $21.49, down 1.94% on the day, with a bullish technical signal from moving averages and strong analyst support. The company demonstrates robust revenue growth, reaching $1.30B in 2025, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its strategic AI partnership with Palantir and expansion of its Athena AI platform, driving positive investor sentiment despite current negative profitability metrics.
The outlook for ZETA is positive, with a consensus price target of $27.50 implying 28% upside. Key opportunities include AI-driven growth and market share gains, but risks involve persistent negative net margins and cash flow challenges. Investors should weigh the strong growth trajectory against profitability concerns before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
